Evidence map›Paper›PMID 34484299›Full record

ArticleFrontiers in genetics2021

Identification and Validation of a PPP1R12A-Related Five-Gene Signature Associated With Metabolism to Predict the Prognosis of Patients With Prostate Cancer.

Zhihao Zou, Ren Liu, Yingke Liang, Rui Zhou, Qishan Dai, Zhaodong Han, Minyao Jiang, Yangjia Zhuo, Yixun Zhang, Yuanfa Feng and 6 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in genetics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Frontiers in veterinary science · 2025
    Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 8 institutions in 2 countries.

Zhihao ZouDepartment of Geriatrics, The Second Affiliated Hospital of South China University of Technology, Guangzhou, China.
Ren LiuGuangdong Provincial Institute of Nephrology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Yingke LiangGuangdong Key Laboratory of Clinical Molecular Medicine and Diagnostics, Department of Urology, School of Medicine, Guangzhou First People's Hospital, South China University of Technology, Guangzhou, China.
Rui ZhouGuangdong Key Laboratory of Clinical Molecular Medicine and Diagnostics, Department of Urology, School of Medicine, Guangzhou First People's Hospital, South China University of Technology, Guangzhou, China.
Qishan DaiGuangdong Key Laboratory of Clinical Molecular Medicine and Diagnostics, Department of Urology, School of Medicine, Guangzhou First People's Hospital, South China University of Technology, Guangzhou, China.
Zhaodong HanGuangdong Key Laboratory of Clinical Molecular Medicine and Diagnostics, Department of Urology, School of Medicine, Guangzhou First People's Hospital, South China University of Technology, Guangzhou, China.
Minyao JiangDepartment of Urology, Huadu District People's Hospital, Southern Medical University, Guangzhou, China.
Yangjia ZhuoGuangdong Key Laboratory of Clinical Molecular Medicine and Diagnostics, Department of Urology, School of Medicine, Guangzhou First People's Hospital, South China University of Technology, Guangzhou, China.
Yixun ZhangGuangdong Key Laboratory of Clinical Molecular Medicine and Diagnostics, Department of Urology, School of Medicine, Guangzhou First People's Hospital, South China University of Technology, Guangzhou, China.
Yuanfa FengGuangdong Key Laboratory of Clinical Molecular Medicine and Diagnostics, Department of Urology, School of Medicine, Guangzhou First People's Hospital, South China University of Technology, Guangzhou, China.
Xuejin ZhuGuangdong Key Laboratory of Clinical Molecular Medicine and Diagnostics, Department of Urology, School of Medicine, Guangzhou First People's Hospital, South China University of Technology, Guangzhou, China.
Shanghua CaiUrology Key Laboratory of Guangdong Province, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, China.
Jundong LinGuangdong Key Laboratory of Clinical Molecular Medicine and Diagnostics, Department of Urology, School of Medicine, Guangzhou First People's Hospital, South China University of Technology, Guangzhou, China.
Zhenfeng TangUrology Key Laboratory of Guangdong Province, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, China.
Weide ZhongGuangdong Key Laboratory of Clinical Molecular Medicine and Diagnostics, Department of Urology, School of Medicine, Guangzhou First People's Hospital, South China University of Technology, Guangzhou, China.
Yuxiang LiangDepartment of Geriatrics, The Second Affiliated Hospital of South China University of Technology, Guangzhou, China.
Guangzhou First People's Hospital · CNGuangzhou Medical University · CNHuizhou Central People's Hospital · CNFirst Affiliated Hospital of Guangzhou Medical University · CNKey Laboratory of Guangdong Province · CNNanfang Hospital · CNSouth China University of Technology · CNSouthern Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundProstate cancer (PCa) is the most common malignant male neoplasm in the American male population. Our prior studies have demonstrated that protein phosphatase 1 regulatory subunit 12A (PPP1R12A) could be an efficient prognostic factor in patients with PCa, promoting further investigation. The present study attempted to construct a gene signature based on PPP1R12A and metabolism-related genes to predict the prognosis of PCa patients.

methodsThe mRNA expression profiles of 499 tumor and 52 normal tissues were extracted from The Cancer Genome Atlas (TCGA) database. We selected differentially expressed PPP1R12A-related genes among these mRNAs. Tandem affinity purification-mass spectrometry was used to identify the proteins that directly interact with PPP1R12A. Gene set enrichment analysis (GSEA) was used to extract metabolism-related genes. Univariate Cox regression analysis and a random survival forest algorithm were used to confirm optimal genes to build a prognostic risk model.

resultsWe identified a five-gene signature (

conclusionThe five-gene signature is an effective potential factor to predict the prognosis of PCa, classifying PCa patients into high- and low-risk groups, which might provide potential novel treatment strategies for these patients.

Indexed as

gene signaturemetabolismprognostic modelprostate cancerprotein phosphatase 1 regulatory subunit 12A

Identifiers

PMID34484299
PMCPMC8414655
OpenAlexW3194892380

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.